Chimeric Antigen Receptor T cell (CAR-T) therapy is an innovative approach in the field of cell therapy, where a patient’s own T-cells are genetically modified ex vivo and infused back to the patient to target and combat specific diseases, particularly cancers. Our expert team of scientists is committed to provide a wide range of services in CAR-T cell therapy research and development.
Speak to our experts
CAR Designing
- CAR discovery (scFv / vHH) and screening
- 2nd / 3rd / 4th generation CAR designing (ScFV /vHH / linkers / co-stimulatory domain testing / safety switches / standard designs / cargo)
- Dual / bi-specific CAR and universal / allogeneic CARs
CAR-T Generation
- Viral vector system (lentivirus / retrovirus)
- Non-viral system (synthetic mRNA / transposon)
- Transduction / transfection of primary T cells or PBMCs from healthy donors
CAR-T Manufacturing Process Optimization
- Media, cytokines, and growth factors screening for ex vivo CAR-T cell manufacturing process optimization
CAR-T Characterization
- CAR detection (% CAR + T cells) by flow cytometry
- Vector copy number (VCN) by dPCR/qRT-PCR
- Immunophenotyping (%CD3+/%CD4+, (%CD3+/%CD8+ CAR-T cells), %TN, %TSCM, %TCM, %TEM, and %TE during and after ex vivo CAR-T expansion
- Activation (CD25) and exhaustion marker (PD-1, LAG-3, TIM3, CTLA-4) analysis
- Cargo expression analysis by flow cytometry
- Degranulation assays
In vitro CAR-T Screening
- CAR-T proliferation (recombinant protein or co-culture (E:T) assay)
- Cytotoxicity assay / co-culture (different E:T ratio) using target expressing parental or reporter cell lines using Incucyte
- T-cell activation (CD25) marker analysis
- T-cell exhaustion marker analysis (PD-1, LAG-3, TIM3, CTLA-4)
- Inflammatory cytokine profiling (IL-2, IFN-y and TNF-a, CD107 a/b)
In vivo CAR-T Efficacy
- Tumor regression or clearance study in orthotopic systemic NOD-SCID/NSG xenograft model (B-cell malignancies) using an in vivo imaging system (IVIS)
- Immunophenotyping of circulating CAR-T cells
- CAR-T activation, proliferation, and persistence assessment by flow cytometry and Vector Copy Number (VCN) analysis
- Cytokine profiling (IL-2, IFN-y, and TNF-a)
Reagent Generation for CAR-T research work
- Lentivirus, retrovirus, synthetic mRNA, transposon system, KI/KO/reporter cell lines, and reagent proteins.
Why Aurigene Cell Therapy Services?
CAR discovery
CAR designing and screening
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
Accelerating Drug Discovery Through Innovative Partnerships
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....
Read More
Physiochemical Characterization Services
Backed by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...
Read More
Expediting early development through innovative precision capsule filling technology
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...
Read More
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market